SCHEMBL21553130

SCHEMBL21553130

CCOC(=O)/C=C/c1cn(-c2ccc(S(=O)(=O)N(C)C)cc2)c(=O)c(N2CCN(C(=O)O)CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 1/20 0.37
TGM2 P21980 1/20 0.37
TGM1 P22735 1/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 2/20 0.36
KMT2A Q03164 5/20 0.35
MEN1 O00255 3/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ADRB2 P07550 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
GPR55 Q9Y2T6 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21564613 0.91 POLB (0.38) POLBMAPTRAB9ANPC1LMNA
SCHEMBL21564477 0.90 KMT2A (0.40) F13A1TGM2TGM1MAPTLMNA
SCHEMBL21553097 0.87 IDO1 (0.40) POLBSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL21552906 0.82 L3MBTL1 (0.41) SMN1; SMN2MAPTRAB9ALMNAKMT2A
SCHEMBL21552976 0.81 ATM (0.38) SMN1; SMN2MAPTKMT2AMEN1ADRB2
SCHEMBL21564784 0.80 MTOR (0.43) SMN1; SMN2MAPTLMNAKMT2AMEN1
SCHEMBL21564614 0.79 ALDH1A1 (0.39) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL21553127 0.77 SMN1; SMN2 (0.37) SMN1; SMN2MAPTLMNAKMT2AMEN1
SCHEMBL21564467 0.77 CNR1 (0.43) POLBMAPTRAB9ANPC1LMNA
SCHEMBL21553117 0.76 SMN1; SMN2 (0.38) SMN1; SMN2MAPTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A F13A1 1870/4885TGM2 1901/4885TGM1 1545/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A F13A1 1870/4885TGM2 1901/4885TGM1 1545/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A F13A1 1781/4885TGM2 2146/4885TGM1 1557/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A F13A1 1870/4885TGM2 1901/4885TGM1 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.